resTORbio, Inc. (TORC): Price and Financial Metrics


resTORbio, Inc. (TORC): $15.96

-0.63 (-3.80%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TORC to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

TORC Stock Price Chart Interactive Chart >

Price chart for TORC

TORC Price/Volume Stats

Current price $15.96 52-week high $17.22
Prev. close $2.37 52-week low $0.86
Day low $15.47 Volume 121,614
Day high $17.22 Avg. volume 1,153,737
50-day MA $2.34 Dividend yield N/A
200-day MA $1.72 Market Cap 581.81M

resTORbio, Inc. (TORC) Company Bio


resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases and conditions in the United States. It is developing TORC1 inhibitor class of pharmaceutical products, including RTB101 and RTB101 with everolimus that are in Phase IIb clinical trial for the treatment of respiratory tract infections; and that have completed Phase I clinical trials for the treatment of heart failure with preserved ejection fraction and autophagy-related neurodegenerative diseases, as well as other infections, such as urinary tract infections. The company was founded in 2016 and is based in Boston, Massachusetts. resTORbio, Inc. is a subsidiary of PureTech Health plc.


TORC Latest News Stream


Event/Time News Detail
Loading, please wait...

TORC Latest Social Stream


Loading social stream, please wait...

View Full TORC Social Stream

Latest TORC News From Around the Web

Below are the latest news stories about resTORbio Inc that investors may wish to consider to help them evaluate TORC as an investment opportunity.

Adicet Announces Completion of Merger with resTORbio

\- Adicet Emerges as a Leading Allogeneic Gamma Delta T Cell Therapy Company Focused on Oncology - -Trading to Commence on September 16, 2020 on The Nasdaq Global Market Under Ticker Symbol “ACET”-MENLO PARK, Calif. and BOSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the completion of its previously announced merger with resTORbio, Inc. (previously trading on Nasdaq under the symbol “TORC”). The new combined company will operate under the name Adicet Bio, Inc. and will commence trading on the Nasdaq Global Market under the ticker symbol “ACET” on September 16, 2020.Adicet will focus on advancing its pipeline of “off-the-shelf” gamma ...

Yahoo | September 15, 2020

SHAREHOLDER ALERT: WeissLaw LLP Reminds TORC and INWK Shareholders About Its Ongoing Investigations

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

Yahoo | August 22, 2020

Adicet Bio Receives $10 Million Product Development Milestone From Regeneron

Adicet Bio, Inc., a privately-held biopharmaceutical company, today announced that it has received a $10 million milestone payment from Regeneron associated with ADI-002 meeting key preclinical development goals, in accordance with the terms of its strategic collaboration with Regeneron. ADI-002 is the first of Adicet Bio's allogeneic off-the-shelf γδ T cell product candidates to specifically target solid tumors. ADI-002 is being developed and engineered by Adicet to express a GPC3-targeting chimeric antigen receptor and IL-15.

Yahoo | August 5, 2020

SHAREHOLDER ALERT: WeissLaw LLP Reminds TORC and VSLR Shareholders About Its Ongoing Investigations

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

Yahoo | July 25, 2020

ALERT: Halper Sadeh LLP is Investigating Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - MXIM, INWK, TORC

NEW YORK, NY / ACCESSWIRE / July 18, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating whether the following mergers are fair to shareholders.

Yahoo | July 18, 2020

Read More 'TORC' Stories Here

TORC Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year -70.96%
5-year N/A
YTD N/A
2021 N/A
2020 0.00%
2019 -82.71%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4565 seconds.